Join our smart investors - Get the best stock directories in  blockchain, cannabis, crypto, AI, IoT, cleantech. Daily podcasts in cannabis and crpto. Just $99  a year

Investor Ideas #Potcasts; #Cannabis News and Stocks on the Move; TSXV: $N.V, TSXV: $OGi.V, CSE: $CHV.C

July 23rd Potcast sponsored by Lexaria Bioscience Corp. (CSE: $LXX.C) (OTC: $LXRP) a #Cannabis company with a new disruptive drug delivery platform: DehydraTECH

Investorideas.com podcasts

 

Pt. Roberts, WA; Delta, BC - July 23, 2018 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its "potcast' site, www.potcasts.ca release today's edition of its series, Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

http://www.investorideas.com/Audio/Podcasts/2018/072318-StocksToWatch.mp3

Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: TSXV: N, TSXV: OGi, CSE: CHV

Today's podcast overview/transcript:

Good morning and welcome to another Investorideas.com potcast ; looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.

Today's potcast was sponsored by Kelowna based Lexaria Bioscience Corp trading on the CSE under symbol LXX and on the OTC as LXRP. Lexaria has developed a new disruptive drug delivery platform: DehydraTECH The Company's patented technology changes the way Active Pharmaceutical Ingredients ("APIs") enter the body orally:

1) Masks unwanted tastes - eliminates the need for sugar-filled edibles.

2) Reduces time of onset - effects are felt within 15-20 min vs. 60-120 min.

3) Avoids first-pass liver metabolism

4) Increases bio-absorption by 5-10X

The Company's DehydraTECH™ technology is patent-protected for multiple APIs: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, Nicotine and Fat soluble vitamins.

Learn more about Lexaria at www.lexariabioscience.com

Today's podcast features news announcements from Namaste Technologies Inc. (TSXV:: N and OTCQB: NXTTF) , Organigram Holdings Inc. (TSX-V: OGI and  OTCQB: OGRMF ) and Canada House Wellness Group Inc. ( CSE : CHV).

But first, Frost & Sullivan's recent analysis on medical cannabis finds that the total revenue of this market in the United States is expected to grow from $5.32 billion in 2017 to $10 billion in 2022, at a compound annual growth rate (CAGR) of 13.6%. Even though the Food and Drug Administration (FDA) has approved only a few medical marijuana-derived products, there will be a strong growth trajectory over the next few years. Much of the current medical cannabis revenue is currently generated in states where the use of marijuana plant products for medical indications has been legalized. Revenue projections suggest that the medical segment of the market may surpass the recreational revenue segment in the next four years, as patients in states where marijuana is legal look for alternatives to opioids to treat their chronic pain.

"Several pharmaceutical companies are working on the development of cannabidiol (CBD)-based receptor agonist drugs. To do so, they need to be aware of the guidelines the FDA sets for the approval of these drugs to advance the therapeutics to the market," noted Barbara Gilmore, Transformational Health Senior Consultant at Frost & Sullivan. "The FDA advisory committee recently approved a cannabinoid receptor agonist drug called Epidiolex, which when launched will be the first FDA-approved, CBD-derived drug on the US market for the treatment of epilepsy."

Namaste Technologies Inc. announce the filing of its unaudited quarterly financial statements, management's discussion and analysis and certification of the quarterly filings for the third quarter of fiscal 2018. The statements for the period can be accessed on the Company's SEDAR profile at www.sedar.com.

The Company's net revenues for the three months ended May 31, 2018 were $4.1 million (2017 - $3.1 million), which is an increase of $1.0 million or 32% as compared to the three months ended May 31, 2017. The increase in net revenues during the third quarter of 2018 was primarily due to organic growth in the Company.

The Company's net revenues for the nine months ended May 31, 2018 were $14.6 million (2017 - $7.1 million), which is an increase of $7.5 million or 106% as compared to the nine months ended May 31, 2017 despite having divested the Company's U.S. business in December 2017. The increase in net revenues during the nine months ended May 31, 2018 was primarily due to revenue growth from EDIT domains and Australian Vaporizers. EDIT domains were acquired in October 2016 and Australian Vaporizers was acquired in March 2017.

Namaste Technologies Inc. also announced that the Company has submitted its application to list its common shares on the NASDAQ Capital Market ("NASDAQ").

In advance of the listing on NASDAQ, Namaste will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission. The listing of the Company's common shares on NASDAQ remains subject to the approval of NASDAQ and the satisfaction of all applicable listing and regulatory requirements, including the effectiveness of the Form 40-F Registration Statement. The Company may also seek shareholder approval for a share consolidation in order to meet the share-price requirements of NASDAQ.

Organigram Holdings Inc., the parent company of Organigram Inc., a leading licensed producer of medical marijuana based in Moncton, New Brunswick, is in the final stages of planting the remaining three of the sixteen three-tier Phase 3 cultivation rooms which have been licensed by Health Canada. In total, the Company's Phase 3 expansion has increased Organigram's target dried flower equivalent production capacity from an estimated 22,000 kg/annum (Phases 1 and 2) to 36,000 kg/annum (Phases 1, 2 and 3).

Staggered harvests from Phase 3 are expected to begin in late August. The licensing of Phase 3 does not require a new sales license as this expansion is part of the existing Moncton facility. The additional capacity will help ensure product is available for sale when the adult recreational market launches.

In addition, Organigram has received licensing on a second harvest room which allows the Company to automate its harvesting process. The Company has also received licensing on new automated potting and waste shredding rooms.

Canada House Wellness Group Inc. announced that its wholly owned subsidiary, Abba Medix Corp. ("Abba"), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR") has successfully completed its Health Canada pre-sales inspection and has received an amendment to its Producer's Licence from Health Canada to include the sale and provision of marihuana seeds, effective July 20, 2018. 

To support this sales license Abba has secured an exclusive Canadian distribution agreement with a well-established UK seed producer and now has access to more than 800 cannabis strains. More than 200 of these strains are immediately available for sale by Abba.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment

This podcast is sponsored by Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com

Sign up to get the news alerts including the daily podcast and transcript for Investor ideas potcasts

Subscribe to the new cannabis podcast series:

http://www.investorideas.com/rss/feeds/Podcasts-Cannabis.xml

Or visit http://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

To hear more Investorideas.com podcasts visit: http://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Google Play Music, Stitcher and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Ideas

Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.

Investorideas.com cannabis/marijuana and hemp content now includes http://cannabisstocknews.blogspot.com on Blogger.com: the Investorideas.com news and stock directory pages, a cannabis investor group on Linkedin.com , the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the new AI site Global Cannabis Investing at www.Globalcannabisinvesting.com

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) is a media sponsor of the podcast starting July 5 2018 more info http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: http://www.investorideas.com/About/Private_Policy.asp

To sponsor this podcast or be a guest

Contact Investorideas.com

http://www.investorideas.com/About/Contact.asp

800-665-0411


Do you trade or invest in Marijuana / Hemp Stocks? Check out our stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana / Hemp Stocks

Join our Group on Linkedin and talk about - Marijuana / Hemp Stocks - News and Trends in Green Investing